Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment (BRAVO)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Osteoporosis, Postmenopausal

Treatments: Other: OPSAT-Q

Study type: Observational

Funder types: Industry

Identifiers

NCT01227369

111720

Details and patient eligibility

About

Quality of Life (QoL) in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Full description

Cross-sectional quality of life survey using self-administered OPSAT-QTM questionnaire in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Enrollment: 4,376 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Who have been diagnosed with postmenopausal osteoporosis by physician Who have received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide answer of OPSAT-QTM questionnaire Who provide informed consent for study participation

Exclusion criteria

• Do not understand the contents of the questionnaire

Trial design

4,376 participants in 1 patient group

Bisphosphonates

Description:

Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Treatment:

Other: OPSAT-Q